ERBB2 and breast carcinoma: Dato-DXd is approved for use in unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer in patients who have received prior endocrine-based therapy and chemotherapy [23], and for patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC who have received prior EGFR-targeted therapies [24,25].